With the initial focus to help guide Open Orphan in the provision of solutions to Coronavirus outbreak
Open Orphan PLC (LON:ORPH) Appointment of Professor Oxford as Chair of Advisory Board
Open Orphan PLC (LON:ORPH) Appointment of Group Chief Financial Officer
Cathal Friel, Executive Chairman of Open Orphan said: “I am delighted that we have appointed Leo as CFO. He has worked with Open Orphan for the past year and is
Open Orphan PLC (LON:ORPH) Upcoming Investor Events & Investor Presentation
Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine
Open Orphan PLC (LON:ORPH) New Corporate Presentation
Open Orphan plc (ORPH), the rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce the latest copy of its investor presentation is
Novacyt S.A. (LON:NCYT) Launch of novel coronavirus test
Graham Mullis, Chief Executive Officer of Novacyt commented. Over the last few days, we have seen significant early demand for our genesig® 2019-nCoV test from over 10 countries.
Ergomed plc (LON:ERGO) 2019 Trading Update
Ergomed plc (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, announces a trading update for the year ended 31 December 2019.
Open Orphan PLC (LON:ORPH) Update on Placing & Studio Interview
Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, confirms that as previously announced it is currently undertaking meetings with investors
Cathal Friel, Executive Chairman of Open Orphan PLC (LON:ORPH)
Open Orphan Plc announced the completion of its acquisition of UK-based hVivo Plc on Monday, 20th January 2020.
Integumen PLC (LON:SKIN) signs cooperative alliance MOU with Innocare Group, Shanghai, China
Trading update: Unaudited Revenues up 366% to £1m
Open Orphan PLC (LON:ORPH) Completion of Merger with hVIVO and Re-Admission
Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext
Open Orphan PLC (LON:ORPH) Offer Wholly Unconditional
On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and
and then 